GlassScriptPhysician profile
Nikhat Nafeeza Khan
NPI 1295316891
$1,641.28
in general payments reported to CMS, 2019-2025
27 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $49.53 · 2024: $374 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $190.80 | 2024-2025 | Airsupra, Bevespi Aerosphere |
| E.R. Squibb & Sons, L.L.C. | $180.81 | 2025 | Eliquis |
| Exact Sciences Corporation | $169.80 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $104.88 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $97.58 | 2024-2025 | Gemtesa |
| Novo Nordisk INC | $93.37 | 2025 | Ozempic, Rybelsus |
| Pfizer INC. | $77.83 | 2024-2025 | |
| Abbvie INC. | $75.43 | 2024-2025 | |
| Ardelyx, INC. | $73.38 | 2025 | Ibsrela |
| Lilly USA, LLC | $70.34 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $69.37 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.04 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $48.50 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $42.71 | 2023-2025 | Veozah, Myrbetriq |
| Philips North America LLC | $37.22 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.97 | 2025 | |
| Sanofi-Aventis U.S. LLC | $30.51 | 2025 | |
| Inspire Medical Systems, INC. | $27.66 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $23.38 | 2025 | Capvaxive, Gardasil 9 |
| Seqirus USA INC | $23.09 | 2025 | Flucelvax, Fluad |
| Eisai INC. | $22.05 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.11 | 2025 | |
| Echosens North America, INC. | $17.75 | 2025 | Fibroscan |
| Actelion Pharmaceuticals US, INC. | $17.63 | 2025 | Opsumit, Uptravi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.19 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2025 | Zoryve |
| Organon LLC | $9.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhat Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.